Correlia Biosystems

Correlia Biosystems, founded in November 2017, is a spinoff from UC Berkeley located in Berkeley, CA, USA. The company operates within the healthcare industry, focusing specifically on diagnostics. Correlia Biosystems develops innovative microscale tools that enable the rapid quantification of biomolecules. One of their key technologies, ‘SimpleScan’, is used for dynamic monitoring of protein expression profiles, with applications ranging from next-generation proteomic data sets to point-of-care diagnostics. Additionally, the company offers advanced blood testing technologies that provide pharma companies with 1000 times more data than traditional methods. With a team of 16 employees, Correlia Biosystems was part of the Y Combinator W18 batch and caters to markets in the United States, Canada, and also supports remote and partly remote work environments. The company is currently in a growth stage, expanding its impact in the field of diagnostics.